Autopsy report · NCT00109798

Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma

“Sub-Investigator reloacted to another institution”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

The Methodist Hospital Research Institute

Sponsor type

University, hospital or other

Conditions

Central Nervous System Tumors; Lymphoma

Interventions

temozolomide; topotecan hydrochloride

Participants

0

Trials that died the same way

• BFR Therapy After ACL Reconstruction
  “Investigator separated from institution” (81% match in meaning)
• Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
  “Investigator Left Institution” (78% match in meaning)
• Performance of Diuretic Stress Test in Predicting Short Term Renal Recovery in Oliguric Critically-ill Patients Recovery in the Short Term
  “departure of the coordinating investigator from another institution” (78% match in meaning)
• A Study of Oral L-citrulline in Sickle Cell Disease
  “Principal Investigator moved to another institution” (77% match in meaning)
• Intralesional Tetracycline Injection in the Treatment of Chalazia
  “Investigator left the institution” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.